Naomi Walsh
Assoc. Prof
Dr. Naomi Walsh is an Associate Professor in the School of Biotechnology/National Institute for Cellular Biotechnology (NICB). Dr Walsh holds a BSc. in Analytical Science and PhD in Biotechnology/Cancer Research from Dublin City University, and a Master's of Public Health (MPH) from University College Dublin. Her PhD research focused on the mechanisms of invasion, metastasis and drug-resistance in pancreatic cancer. Dr. Walsh was awarded the prestigious Cancer Prevention Fellowship Programme (CPFP) where she undertook post-doctoral research in the Laboratory of Human Carcinogenesis under the mentorship of Dr. Curt Harris at the National Cancer Institute (NCI), USA. Dr. Walsh studied prognostic biomarkers that can aid in clinical management for cancer patients. Dr. Walsh also continues to collaborate with Dr. Rachael Stolzenberg-Solomon (DCEG, NCI) on pathway analysis of genome-wide association studies (GWAS) of pancreatic cancer. On her return to Ireland, Dr. Walsh was awarded the Irish Cancer Society Re-integration Grant, and subsequently an SFI Starting Investigator Research Grant (2016-2020). In 2017, Dr. Walsh was awarded the Irish Cancer Society Researcher of the Year. Dr. Walsh's current research is focused on developing organotypic 3D cancer models to define and validate the biological consequences of genomic variants of pancreatic cancer. Her research aims to understand the development of pancreatic cancer, to uncover markers for early detection and to identify those at high risk of pancreatic cancer.
Other interests include understanding tumour diversity caused by genomic alterations which contributes to cancer resistance to chemotherapy funded by Pancreatic Cancer Research Fund PCRF http://www.pcrf.org.uk. Her lab uses genomic and functional NGS approaches to identify the mechanisms of genomic and immunological diversity to develop prognostic/predictive signatures and therapeutic strategies to overcome treatment resistance.
Peer Reviewed Journal
| Year | Publication | |
|---|---|---|
| 2020 | Nelson, S.R.; Zhang, C.; Roche, S.; O’Neill, F.; Swan, N.; Luo, Y.; Larkin, A.M.; Crown, J.; Walsh, N. (2020) 'Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development'. Scientific Reports, 10 . [Link] [DOI] | |
| 2020 | Nelson, SR; Roche, S; Cotter, M; Garcia, PA; Reitmeier, D; Zollbrecht, E; O'Neill, F; Clynes, M; Doolan, P; Medha, JP; Swan, N; Larkin, A; Walsh, N (2020) 'Genomic Profiling and Functional Analysis of let-7c miRNA-mRNA Interactions Identify SOX13 to Be Involved in Invasion and Progression of Pancreatic Cancer'. Journal of Oncology, 2020 . [DOI] | |
| 2020 | Walsh, N.; Andrieu, C.; O’Donovan, P.; Quinn, C.; Maguire, A.; Furney, S.J.; Gullo, G.; Crown, J. (2020) 'Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer'. British Journal of Cancer, 123 . [Link] [DOI] | |
| 2020 | Yuan, F.; Hung, R.J.; Walsh, N.; Zhang, H.; Platz, E.A.; Wheeler, W.; Song, L.; Arslan, A.A.; Beane Freeman, L.E.; Bracci, P.; Canzian, F.; Du, M.; Gallinger, S.; Giles, G.G.; Goodman, P.J.; Kooperberg, C.; Le Marchand, L.; Neale, R.E.; Rosendahl, J.; Scelo, G.; Shu, X.O.; Visvanathan, K.; White, E.; Zheng, W.; Albanes, D.; Amiano, P.; Andreotti, G.; Babic, A.; Bamlet, W.R.; Berndt, S.I.; Brennan, P.; Bueno-De-Mesquita, B.; Buring, J.E.; Campbell, P.T.; Chanock, S.J.; Fuchs, C.S.; Michael Gaziano, J.; Goggins, M.G.; Hackert, T.; Hartge, P.; Hassan, M.M.; Holly, E.A.; Hoover, R.N.; Katzke, V.; Kirsten, H.; Kurtz, R.C.; Lee, I.M.; Malats, N.; Milne, R.L.; Murphy, N.; Ng, K.; Oberg, A.L.; Porta, M.; Rabe, K.G.; Real, F.X.; Rothman, N.; Sesso, H.D.; Silverman, D.T.; Thompson, I.M.; Wactawski-Wende, J.; Wang, X.; Wentzensen, N.; Wilkens, L.R.; Yu, H.; Zeleniuch-Jacquotte, A.; Shi, J.; Duell, E.J.; Amundadottir, L.T.; Li, D.; Petersen, G.M.; Wolpin, B.M.; Risch, H.A.; Yu, K.; Klein, A.P.; Stolzenberg-Solomon, R. (2020) 'Genome-wide association study data reveal genetic susceptibility to chronic inflammatory intestinal diseases and pancreatic ductal adenocarcinoma risk'. Cancer Research, 80 . [Link] [DOI] | |
| 2020 | Nelson, SR; Walsh, N (2020) 'Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients'. Cancers, 12 (5). [DOI] | |
| 2020 | Breen, L; Gaule, PB; Canonici, A; Walsh, N; Collins, DM; Cremona, M; Hennessy, BT; Duffy, MJ; Crown, J; Donovan, NO; Eustace, AJ (2020) 'Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A'. Investigational New Drugs, 38 (5). [DOI] | |
| 2019 | Gaule, P.; Mukherjee, N.; Corkery, B.; Eustace, A.J.; Gately, K.; Roche, S.; O’Connor, R.; O’Byrne, K.J.; Walsh, N.; Duffy, M.J.; Crown, J.; O’Donovan, N. (2019) 'Dasatinib treatment increases sensitivity to c-met inhibition in triple-negative breast cancer cells'. Cancers, 11 . [Link] [DOI] | |
| 2018 | Gullo, G; Walsh, N; Fennelly, D; Bose, R; Walshe, J; Tryfonopoulos, D; O'Mahony, K; Hammond, L; Silva, N; McDonnell, D; Ballot, J; Quinn, C; McDermott, EW; Evoy, D; Prichard, R; Geraghty, J; Amstrong, J; Crown, J (2018) 'Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the one thousand HER2 patients project'. British Journal of Cancer, 119 (3). [DOI] | |
| 2014 | O' Sullivan, D; Henry, M; Joyce, H; Walsh, N; Mc Auley, E; Dowling, P; Swan, N; Moriarty, M; Barnham, P; Clynes, M; Larkin, A (2014) '7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells'. Tumor Biology, 35 :6983-6997. [DOI] | |
| 2017 | Canonici, A; Qadir, Z; Conlon, NT; Collins, DM; O'Brien, NA; Walsh, N; Eustace, AJ; O'Donovan, N; Crown, J (2017) 'The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells'. Investigational New Drugs, 36 (4). [DOI] | |
| 2018 | Eustace, AJ; Conlon, NT; McDermott, MSJ; Browne, BC; O'Leary, P; Holmes, FA; Espina, V; Liotta, LA; O'Shaughnessy, J; Gallagher, C; O'Driscoll, L; Rani, S; Madden, SF; O'Brien, NA; Ginther, C; Slamon, D; Walsh, N; Gallagher, WM; Zagozdzon, R; Watson, WR; O'Donovan, N; Crown, J (2018) 'Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL'. BMC Cancer, 18 (1). [DOI] | |
| 2019 | Walsh, N.; Zhang, H.; Hyland, P.L.; Yang, Q.; Mocci, E.; Zhang, M.; Childs, E.J.; Collins, I.; Wang, Z.; Arslan, A.A.; Beane-Freeman, L.; Bracci, P.M.; Brennan, P.; Canzian, F.; Duell, E.J.; Gallinger, S.; Giles, G.G.; Goggins, M.; Goodman, G.E.; Goodman, P.J.; Hung, R.J.; Kooperberg, C.; Kurtz, R.C.; Malats, N.; Lemarchand, L.; Neale, R.E.; Olson, S.H.; Scelo, G.; Shu, X.O.; Van Den Eeden, S.K.; Visvanathan, K.; White, E.; Zheng, W.; Albanes, D.; Andreotti, G.; Babic, A.; Bamlet, W.R.; Berndt, S.I.; Borgida, A.; Boutron-Ruault, M.C.; Brais, L.; Bueno-De-Mesquita, B.; Buring, J.; Chaffee, K.G.; Chanock, S.; Cleary, S.; Cotterchio, M.; Foretova, L.; Fuchs, C.; M Gaziano, J.M.; Giovannucci, E.; Hackert, T.; Haiman, C.; Hartge, P.; Hasan, M.; Helzlsouer, K.J.; Herman, J.; Holcatova, I.; Holly, E.A.; Hoover, R.; Janout, V.; Klein, E.A.; Laheru, D.; Lee, I.M.; Lu, L.; Mannisto, S.; Milne, R.L.; Oberg, A.L.; Orlow, I.; Patel, A.V.; Peters, U.; Porta, M.; Real, F.X.; Rothman, N.; Sesso, H.D.; Severi, G.; Silverman, D.; Strobel, O.; Sund, M.; Thornquist, M.D.; Tobias, G.S.; Wactawski-Wende, J.; Wareham, N.; Weiderpass, E.; Wentzensen, N.; Wheeler, W.; Yu, H.; Zeleniuch-Jacquotte, A.; Kraft, P.; Li, D.; Jacobs, E.J.; Petersen, G.M.; Wolpin, B.M.; Risch, H.A.; Amundadottir, L.T.; Yu, K.; Klein, A.P.; Stolzenberg-Solomon, R.Z. (2019) 'Agnostic Pathway/Gene Set Analysis of Genome-Wide Association Data Identifies Associations for Pancreatic Cancer'. Journal of the National Cancer Institute, 111 . [Link] [DOI] | |
| 2017 | Noro, R; Ishigame, T; Walsh, N; Shiraishi, K; Robles, AI; Ryan, BM; Schetter, AJ; Bowman, ED; Welsh, JA; Seike, M; Gemma, A; Skaug, V; Mollerup, S; Haugen, A; Yokota, J; Kohno, T; Harris, CC (2017) 'A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts'. Journal of Thoracic Oncology, 12 :65-76. [DOI] | |
| 2015 | Mahgoub, T; Eustace, AJ; Collins, DM; Walsh, N; O'Donovan, N; Crown, J (2015) 'Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma'. International Journal of Oncology, 47 (3). [DOI] | |
| 2014 | O' Sullivan, D; Henry, M; Joyce, H; Walsh, N; Mc Auley, E; Dowling, P; Swan, N; Moriarty, M; Barnham, P; Clynes, M; Larkin, A (2014) '7B7: a novel antibody directed against the Ku70/Ku80 heterodimer blocks invasion in pancreatic and lung cancer cells'. Tumor Biology, 35 :6983-6997. [DOI] | |
| 2012 | Walsh, N; Kennedy, S; Larkin, A; Corkery, B; O'Driscoll, L; Clynes, M; Crown, J; O'Donovan, N (2012) 'EGFR and HER2 inhibition in pancreatic cancer'. Investigational New Drugs, 31 (3). [DOI] | |
| 2011 | Walsh, N; Larkin, A; Swan, N; Conlon, K; Dowling, P; McDermott, R; Clynes, M (2011) 'RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation'. Cancer Letters, 306 :180-189. [DOI] | |
| 2022 | Andrieu, C; McNamee, N; Larkin, AM; Maguire, A; Menon, R; Mueller-Eisert, J; Horgan, N; Kennedy, S; Gullo, G; Crown, J; Walsh, N (2022) 'Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes'. Medical Sciences (Basel, Switzerland), 10 (2). [DOI] | |
| 2008 | Dowling, P; Walsh, N; Clynes, M (2008) 'Membrane and membrane-associated proteins involved in the aggressive phenotype displayed by highly invasive cancer cells'. Proteomics, 8 (19). [DOI] | |
| 2020 | Goldrick, C; Palanga, L; Tang, B; Mealy, G; Crown, J; Horgan, N; Kennedy, S; Walsh, N (2020) 'Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal Melanoma'. Journal of Cancer, 12 (15). [DOI] | |
| 2024 | Kennedy, S; Owens, S; Ivers, L; Hegarty, C; O'Neill, V; Berenguer-Pina, JJ; Horgan, N; Crown, J; Walsh, N (2024) 'Prognostic Value of BAP1 Protein Expression in Uveal Melanoma'. The American journal of surgical pathology, . [DOI] | |
| 2024 | Myers, S.H.; Poppi, L.; Rinaldi, F.; Veronesi, M.; Ciamarone, A.; Previtali, V.; Bagnolini, G.; Schipani, F.; Ortega Martínez, J.A.; Girotto, S.; Di Stefano, G.; Farabegoli, F.; Walsh, N.; De Franco, F.; Roberti, M.; Cavalli, A. (2024) 'An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer'. European Journal of Medicinal Chemistry, 265 . [Link] [DOI] | |
| 2023 | Curley, R.C.; Burke, C.S.; Gkika, K.S.; Noorani, S.; Walsh, N.; Keyes, T.E. (2023) 'Phototoxicity of Tridentate Ru(II) Polypyridyl Complex with Expanded Bite Angles toward Mammalian Cells and Multicellular Tumor Spheroids'. Inorganic Chemistry, 62 . [Link] [DOI] | |
| 2021 | Gkika, K.S.; Noorani, S.; Walsh, N.; Keyes, T.E. (2021) 'Os(II)-Bridged Polyarginine Conjugates: The Additive Effects of Peptides in Promoting or Preventing Permeation in Cells and Multicellular Tumor Spheroids'. Inorganic Chemistry, 60 . [Link] [DOI] | |
| 2011 | Walsh, N; Larkin, A; Swan, N; Conlon, K; Dowling, P; McDermott, R; Clynes, M (2011) 'RNAi knockdown of Hop (Hsp70/Hsp90 organising protein) decreases invasion via MMP-2 down regulation'. Cancer Letters, 306 (2). [DOI] |
Review Articles
| Year | Publication | |
|---|---|---|
| 2020 | Nelson, Shannon R.; Walsh, Naomi (2020) Genetic Alterations Featuring Biological Models to Tailor Clinical Management of Pancreatic Cancer Patients. REV [DOI] | |
| 2010 | Sheikh, Rizwan; Walsh, Naomi; Clynes, Martin; O'Connor, Robert; McDermott, Ray (2010) Challenges of drug resistance in the management of pancreatic cancer. REV [DOI] |
Other Publication
| Year | Publication | |
|---|---|---|
| 2017 | Walsh, N.; Gullo, G.; Maguire, A.; O'Donovan, N.; Quinn, C.; Crown, J. (2017) Genomic copy number alterations (CNA) associated with pCR in HER2-positive (HER2+) early-stage breast cancer (BrCa) patients receiving neoadjuvant trastuzumab (T). [DOI] | |
| 2017 | Gullo, G.; Walsh, N.; Fennelly, D.; Tryphonopoulos, D.; Walshe, J.; O'Mahony, K.; Silva, N.; Hammond, L.; Ballot, J.; Quinn, C.; Buckley, C.; Crown, J. (2017) Timing of initiation of trastuzumab (T) and long-term outcome of patients (pts) with early-stage (ES) HER2-positive (HER2+) breast cancer (BrCa): Impact of neo-adjuvant (NAdj) versus adjuvant (Adj) strategy. | |
| 2017 | Gullo, G.; Walsh, N.; Zacchia, A.; Hammond, L.; Fennelly, D.; Walshe, J.; O'Mahony, K.; Maltese, M.; Crown, J. (2017) Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx). | |
| 2016 | Gullo, G.; Bose, R.; Walsh, N.; Maltese, M.; Fennelly, D.; Walshe, J.; Ballot, J.; Crown, J. (2016) Delayed initiation of HER2-targeted therapy (HER2Tx) is associated with a higher risk of relapse for early stage (ES) HER2-positive (HER2+) breast cancer (BrCa). [DOI] | |
| 2016 | Noro, Rintaro; Walsh, Naomi; Ishigame, Teruhide; Shiraishi, Kouya; Robles, Ana I.; Ryan, Brid M.; Bowman, Elise; Welsh, Judith A.; Schetter, Aaron J.; Skaug, Vidar; Mollerup, Steen; Haugen, Aage; Yokota, Jun; Kohno, Takashi; Harris, Curtis C. (2016) Gene expression classifier for prognosis of early-stage squamous cell carcinoma of the lung. | |
| 2006 | Walsh, Naomi; Kennedy, Susan; Larkin, Annemarie; Roy, Shunil; Seong, Wei Ooi; Gullo, Guiseppe; Ballot, Jo; Clynes, Martin; Crown, John; O'Driscoll, Lorraine (2006) MDR1/P-glycoprotein and MRP-1 protein expression in pancreatic (CaP) & non-small cell lung cancers (NSCLC). | |
| 2010 | Sheikh, R.; Walsh, N.; Clynes, M.; Oconnor, R.; McDermott, R. (2010) Challenges of drug resistance in the management of pancreatic cancer. [Link] [DOI] | |
| 2021 | Lee, Cha Len; Walsh, Naomi; Keane, Fergus; Lynch, Emer; Reddan, Tadhg; Craig, Helen; O'Meara, Aileen; Smith, Deirdre; O'Neill, Valerie; Horgan, Noel; Kennedy, Susan; Gullo, Giuseppe; Crown, John (2021) Long-term survival outcomes with immune checkpoint inhibitors (ICI) in metastatic uveal melanoma (MUM). [DOI] | |
| 2021 | Skrobo, Darko; Walsh, Naomi; Berenguer, Jose; Walshe, Janice Maria; Higgins, Michaela Jane; Fennelly, David William; Ballot, Jo; Quinn, Cecily; Gullo, Giuseppe; Crown, John (2021) Clinicopathological characteristics of exceptional responders who achieve durable remissions beyond five years (DR5) in HER2+(H+) metastatic breast cancer (MBC). [DOI] | |
| 2021 | Nelson, Shannon R.; Andrieu, C.; Crown, J.; Harold, D.; Walsh, N. (2021) Analysis of the role of maturity onset diabetes of the young (MODY) pathway transcription factors in pancreatic cancer. | |
| 2021 | Berenguer-Pina, J. J.; Quinn, C. M.; Gullo, G.; Skrobo, D.; Buckley, C.; Walshe, J. M.; Fennelly, D.; Higgins, M.; Ballot, J.; Mccartan, D.; Walsh, N.; Crown, J. P. (2021) Substantial reduction in the percentage of metastatic breast cancer (MBC) which is HER-2 positive (HER-2+) over two decades: Sequential cohort analysis from the 1000 patient HER-2 study. [DOI] | |
| 2022 | Castel, Myra E.; Conlon, Neil T.; Walsh, Naomi; Diala, Irmina; Eli, Lisa; Crown, John; Collins, Denis M. (2022) Comparative time course analysis of the effects of neratinib, lapatinib and tucatinib in an in vitro HER2+breast cancer model. [DOI] | |
| 2022 | Andrieu, Charlotte; Goldrick, Caoimhe; Skrobo, Darko; Eustace, Alex; Ballot, Jo; Quinn, Cecily; Gullo, Giuseppe; Walsh, Naomi; Crown, John (2022) Whole genome sequencing of HER2+metastatic breast cancer and CNA comparison between long term survivor and short-term survivor. |
Certain data included herein are derived from the © Web of Science (2024) of Clarivate. All rights reserved.
Research Interests
Cancer is a disease of the genome. Genomic variants, somatic mutations and alterations can change the function of genes, either promoting the expression of cancer causing genes or the loss of cancer suppressor genes. These genomic variants, mutations/alterations drive cancer predisposition, development, progression and ultimately drug resistance.
Recently, the landscape of pancreatic cancer has been redefined through gene expression and genetic diversity signatures using next generation sequencing (NGS) profiling, while GWAS have identified susceptibility loci associated with pancreatic cancer risk. However, the clinical utility of these biomarkers is lacking. My research involves developing organotypic 3D models to define their relevance as diagnostic/prognostic biomarkers and delinate their role in pancreatic cancer development and progression.
Other research interests are to elucidate the tumour diversity caused by genomic alterations which contributes to cancer resistance to chemotherapy and molecular targeted therapies in breast cancer and melanoma. We use genomic and functional genomic NGS approaches to identify the mechanisms of genomic diversity to develop prognostic/predictive signatures and therapeutic strategies to overcome treatment resistance.
Recently, the landscape of pancreatic cancer has been redefined through gene expression and genetic diversity signatures using next generation sequencing (NGS) profiling, while GWAS have identified susceptibility loci associated with pancreatic cancer risk. However, the clinical utility of these biomarkers is lacking. My research involves developing organotypic 3D models to define their relevance as diagnostic/prognostic biomarkers and delinate their role in pancreatic cancer development and progression.
Other research interests are to elucidate the tumour diversity caused by genomic alterations which contributes to cancer resistance to chemotherapy and molecular targeted therapies in breast cancer and melanoma. We use genomic and functional genomic NGS approaches to identify the mechanisms of genomic diversity to develop prognostic/predictive signatures and therapeutic strategies to overcome treatment resistance.
Research Projects
Teaching Interests
BE226 - Physiological Systems
BE323 - Advanced Cell Biology
BE435 - Animal Cell Biotechnology BE529AU - Molecular Diagnostics BE538 - Intro into Cell Biology & Biotechnology